Global Template for Sharing Biosimilar Assessment Data Suggested By Regulators Group
This article was originally published in The Pink Sheet Daily
Executive Summary
Proposal suggests condensing key data and findings into under 10 pages, published in English.
You may also be interested in...
Latin America: How Regulatory Transparency Can Tackle Non-Comparable Biologics
Non-comparable biologics are a common problem in Latin America as they could deter companies with true biosimilars from entering the market. Among the solutions are better regulatory transparency and action to deal with “non-comparables” already on the market, says FIFARMA, the Latin American Federation of Pharmaceutical Industry.
Manufacturing Regulatory Updates In Brief: Gelcaps, Co-Crystals And Biosimilars
FDA announces reporting change for hard gel capsules and wants to reclassify co-crystals; IPRF releases biosimilars template.
Manufacturing Regulatory Updates In Brief: Gelcaps, Co-Crystals And Biosimilars
FDA announces reporting change for hard gel capsules and wants to reclassify co-crystals; IPRF releases biosimilars template.